Dr. Reddy's Laboratories Limited

Dr Reddys Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 1243, up 1.8% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.48% on the day, quoting at 22670.45. The Sensex is at 72410.69, down 0.5%. Dr Reddys Laboratories Ltd has gained around 7.67% in last one month. Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has gained around 1.12% in last one month and is currently quoting at 26761.65, up 0.45% on the day. The volume in the stock stood at 34.38 lakh shares today, compared to the daily average of 14.98 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 1242.5, up 1.5% on the day. Dr Reddys Laboratories Ltd is up 1.58% in last one year as compared to a 7.89% slide in NIFTY and a 25.3% slide in the Nifty Pharma index.The PE of the stock is 153.77 based on TTM earnings ending June 26.

Dr Reddys Laboratories Ltd is up for a fifth straight session today. The stock is quoting at Rs 1213, up 0.17% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.51% on the day, quoting at 23448.85. The Sensex is at 74901.08, up 0.5%. Dr Reddys Laboratories Ltd has gained around 1.93% in last one month. Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has gained around 2.32% in last one month and is currently quoting at 26909.6, up 0.15% on the day. The volume in the stock stood at 5.57 lakh shares today, compared to the daily average of 14.49 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 1212.3, up 0.44% on the day. Dr Reddys Laboratories Ltd is down 6.56% in last one year as compared to a 6.42% slide in NIFTY and a 21.5% slide in the Nifty Pharma index.The PE of the stock is 152.45 based on TTM earnings ending June 26.

Dr. Reddy’s Laboratories Ltd. will hold a board meeting on October 23, 2026, to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ending September 30, 2026, and the trading window for dealing in securities of the company will be closed from September 24, 2026, to October 25, 2026, inclusive.

Dr. Reddy’s Laboratories Ltd. will hold a board meeting on October 23, 2026, to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ending September 30, 2026, and the trading window for dealing in securities of the company will be closed from September 24, 2026, to October 25, 2026, inclusive.

Dr Reddys Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 1208.6, up 1.99% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.29% on the day, quoting at 23413.6. The Sensex is at 74818.76, up 0.71%. Dr Reddys Laboratories Ltd has risen around 1.56% in last one month. Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has risen around 2.67% in last one month and is currently quoting at 26710.1, up 1.25% on the day. The volume in the stock stood at 8.06 lakh shares today, compared to the daily average of 13.35 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 1205.3, up 1.81% on the day. Dr Reddys Laboratories Ltd is down 7.13% in last one year as compared to a 7.1% drop in NIFTY and a 20.91% drop in the Nifty Pharma index.The PE of the stock is 147.31 based on TTM earnings ending June 26.

Dr. Reddy’s Laboratories Ltd. announced the allotment of 375 equity shares of Re. 1/- each to eligible employees on September 10, 2026, following the exercise of stock options under the Dr. Reddy’s Employees ADR Stock Option Scheme, 2007, resulting in a total issued share capital of Rs. 83,46,81,285 /- and 83,46,80,285 equity shares.

Dr. Reddy’s Laboratories Ltd. announced the allotment of 4,110 equity shares of Re. 1/- each to eligible employees on August 26, 2026, pursuant to the exercise of stock options under the Dr. Reddy’s Employees Stock Option Scheme, 2002, resulting in a total issued share capital of Rs. 83,46,80,910 /- and a total issued shares of 83,46,80,910.

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced that the U.S. Food and Drug Administration has approved its rituximab biosimilar, developed and manufactured by Dr. Reddy’s Laboratories, for the U.S. market, with Fresenius Kabi holding the exclusive rights to commercialize the product in the United States. The approval follows a recent Pre-License Inspection at the company's biologics manufacturing facility in Bachupally, Hyderabad, and strengthens Dr. Reddy’s global biosimilars portfolio.

Revenue from operations declined 5.55% YoY to Rs 8,070.5 crore in the quarter ended 30 June 2026. Profit before tax (PBT) dropped 70.98% YoY to Rs 552.6 crore in Q1 FY27. EBITDA slipped 55.72% to Rs 1,008.8 crore in Q1 FY27 compared with Rs 2,278.4 crore in Q1 FY26. EBITDA margin contracted to 12.5% in Q1 FY27 as against 26.7% in Q1 FY26. Revenue from the Global Generics segment declined 4.79% year-on-year to Rs 7,199.3 crore during the quarter. Revenue from the North America business fell 35.38% YoY to Rs 2,204.8 crore, mainly due to lower sales of Lenalidomide. The company launched six new products in the region during the quarter. Revenue from the India business increased 16.76% YoY to Rs 1,717.7 crore, supported by new brand launches, including innovative assets and recently acquired portfolios, along with price increases and higher sales volumes. The company launched seven new brands during the quarter. Revenue from the Europe region grew 13.30% YoY to Rs 1,444 crore, aided by the launch of 24 new generic products. The Emerging Markets segment reported a 30.52% YoY growth in revenue to Rs 1,832.8 crore, driven by new launches, higher volumes and favourable foreign exchange movement. Research and Development (R&D) expenditure stood at Rs 580 crore in Q1 FY27, down 8% year-on-year but up 6% sequentially. R&D expenses accounted for 7.1% of revenue during the quarter, compared with 7.3% in Q1 FY26. The decline was primarily due to lower development spending on biosimilars, while investments remained focused on complex generics, including peptides and biosimilars. Co-Chairman & MD, G V Prasad said: Our Q1 FY27 performance reflected the expected transition beyond lenalidomide revenues, along with an unexpected impact related to semaglutide API. However, our underlying base business continued to deliver healthy doubledigit growth across all key geographies. Our focus remains on improving the health of our base business through disciplined execution and operational excellence, while building our future pipeline of peptides, biosimilars, and innovative assets to deliver long-term growth. Meanwhile, the company's board approved the appointment of Dr Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel and her induction as a member of the Management Council, effective 22 July 2026. Hyderabad-based Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.Powered by Capital Market - Live

Revenue from operations declined 5.55% YoY to Rs 8,070.5 crore in the quarter ended 30 June 2026. Profit before tax (PBT) dropped 70.98% YoY to Rs 552.6 crore in Q1 FY27. EBITDA slipped 55.72% to Rs 1,008.8 crore in Q1 FY27 compared with Rs 2,278.4 crore in Q1 FY26. EBITDA margin contracted to 12.5% in Q1 FY27 as against 26.7% in Q1 FY26. Revenue from the Global Generics segment declined 4.79% year-on-year to Rs 7,199.3 crore during the quarter. Revenue from the North America business fell 35.38% YoY to Rs 2,204.8 crore, mainly due to lower sales of Lenalidomide. The company launched six new products in the region during the quarter. Revenue from the India business increased 16.76% YoY to Rs 1,717.7 crore, supported by new brand launches, including innovative assets and recently acquired portfolios, along with price increases and higher sales volumes. The company launched seven new brands during the quarter. Revenue from the Europe region grew 13.30% YoY to Rs 1,444 crore, aided by the launch of 24 new generic products. The Emerging Markets segment reported a 30.52% YoY growth in revenue to Rs 1,832.8 crore, driven by new launches, higher volumes and favourable foreign exchange movement. Research and Development (R&D) expenditure stood at Rs 580 crore in Q1 FY27, down 8% year-on-year but up 6% sequentially. R&D expenses accounted for 7.1% of revenue during the quarter, compared with 7.3% in Q1 FY26. The decline was primarily due to lower development spending on biosimilars, while investments remained focused on complex generics, including peptides and biosimilars. Co-Chairman & MD, G V Prasad, said: Our Q1 FY27 performance reflected the expected transition beyond lenalidomide revenues, along with an unexpected impact related to semaglutide API. However, our underlying base business continued to deliver healthy doubledigit growth across all key geographies. Our focus remains on improving the health of our base business through disciplined execution and operational excellence, while building our future pipeline of peptides, biosimilars, and innovative assets to deliver long-term growth. Meanwhile, the company's board approved the appointment of Dr Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel and her induction as a member of the Management Council, effective 22 July 2026. Hyderabad-based Dr Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. The scrip slipped 1.95% to settle at Rs 1,183 on the BSE. Powered by Capital Market - Live